Stock Talk
Today, there is an FDA update on the Phase 1 clinical study trial on Sorrento's single dose of STI-1499 in hospitalized patients with moderate Covid 19.
I will leave it up to the interested reader to think what just a few speculative shares in the 10's would be if the study results in patient recovery faster than normal and/or prevents them from progressing and death. This is a speculative notion and I use my favorite word "some" with caution and some optimism - cautious optimism.
Caveats do not need to be said, however I will repeat. not "too much" and we already know here- " something always happens".
All the above said, "If the If's happen - "some may be enough."
From the Sorrento website:
COVID-19 Treatment: COVI-GUARD (Neutralizing Antibody – STI 1499)
Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVI-GUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2 infection.
Inovio Update:
Meanwhile, the market waits to see how things go with Inovio's progress in answering questions on the device called Cellectra to administer their DNA vaccine INO4800.
I am in "some" of both SRNE and INO after trimming a few shares of INO on that severely disappointing whipsaw from the FDA hold on the very day we were led by the overly confident CEO to expect a Phase 2/3 start. As far as C19 vaccines go, I still believe that Inovio's INO 4800 has the potential to be the safest and most effective and practical- to provide protection against C19 and the new variant.
__
ALL in my humble opinion, scroll down and read more..
This site does NOT make Buy / Sell recommendations.
___
